HepeX B

Drug Profile

HepeX B

Alternative Names: exbivirumab; HBV-AB17; HBV-AB19; HBV-XTL; Hepatitis B MAb-XTL; Human anti-HBV-XTL; libivirumab; Monoclonal antibody HBV-XTL; XTL-001

Latest Information Update: 08 Feb 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator XTL Biopharmaceuticals
  • Developer XTL Biopharmaceuticals; Yeda
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatitis B
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hepatitis B

Most Recent Events

  • 31 Jul 2006 Discontinued - Phase-II for Hepatitis B prevention in European Union (Infusion)
  • 31 Jul 2006 Discontinued - Phase-II for Hepatitis B prevention in World (Infusion)
  • 31 Jul 2006 Discontinued - Phase-II for Hepatitis B treatment in Israel (Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top